<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421419</url>
  </required_header>
  <id_info>
    <org_study_id>IRB - 001858</org_study_id>
    <nct_id>NCT02421419</nct_id>
  </id_info>
  <brief_title>Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture</brief_title>
  <official_title>Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth Taylor, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to compare pain relief and efficacy of trigger finger injection
      using a combination of lidocaine/corticosteroid versus corticosteroid injection alone versus
      corticosteroid/saline combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized study comparing pain relief and efficacy of trigger finger
      injection using a combination of lidocaine/corticosteroid versus corticosteroid injection
      alone versus corticosteroid/saline combination.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed; recruitment problems
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 25, 2017</completion_date>
  <primary_completion_date type="Actual">January 25, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS</measure>
    <time_frame>Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, at 6 weeks post-injection and also asked to recollect their pain at time of injection when seen at 6 weeks post-injection</time_frame>
    <description>Visual Analogue Pain Scale (VAS) - measurement of pain on scale of 0 (least) to 10 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Triggering</measure>
    <time_frame>Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, and 6 weeks post-injection</time_frame>
    <description>Patients are asked how often their finger triggers - not at all, rarely, occasionally, or frequently at time intervals indicated in the outcome measure time frame. Count of participants for each of these answers was collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Triggering</measure>
    <time_frame>Patients are assessed pre-injection objectively by investigator and at 6 weeks post-injection subjectively via Patient Survey</time_frame>
    <description>A Green classification number (0-4) is given to each subject pre-injection and at 6 weeks post-injection based on their degree of triggering. 0 = No triggering, no pain; 1 = Pre-triggering; pain, history of catching, but not demonstrable on physical examination; tenderness over the A1 pulley; 2 = Active; demonstrable catching, but the patient can actively extend the digit; 3= Passive; demonstrable catching requiring passive extension or inability to actively flex; and 4 = Contracture; demonstrable catching with a fixed flexion contracture of the PIP joint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Effects</measure>
    <time_frame>Patients are assessed 1 minute post-injection, 10 minutes post-injection, and at 6 week post-injection.</time_frame>
    <description>Incidence of adverse effects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Trigger Finger Disorder</condition>
  <arm_group>
    <arm_group_label>Corticosteroid alone (CS) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid/Lidocaine (CSL) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid/Saline (CSS) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Sodium Phosphate</intervention_name>
    <description>adreno-cortical steroid anti-inflammatory drug</description>
    <arm_group_label>Corticosteroid alone (CS) Group</arm_group_label>
    <arm_group_label>Corticosteroid/Lidocaine (CSL) Group</arm_group_label>
    <arm_group_label>Corticosteroid/Saline (CSS) Group</arm_group_label>
    <other_name>Decadron phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylocaine</intervention_name>
    <description>a local anesthetic agent</description>
    <arm_group_label>Corticosteroid/Lidocaine (CSL) Group</arm_group_label>
    <other_name>Lidocaine HCL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <description>Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
    <arm_group_label>Corticosteroid/Saline (CSS) Group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-90

          -  Male or female (non-pregnant)

          -  Clinically diagnosed trigger digit

          -  Subject is able to provide voluntary, written informed consent

          -  Subject, in the opinion of the clinical investigator, is able to understand the
             clinical investigation and is willing to perform all study procedures and follow-up
             visits.

        Exclusion Criteria:

          -  Age &lt;18 or &gt;90

          -  Pregnant or lactating women

          -  Non-English speaking individuals

          -  Medication contradictions to lidocaine, corticosteroids and/or saline

          -  Prior injection or surgery on the affected finger

          -  Diagnosis of reflex symptomatic dystrophy (RSD) or complex regional pain syndrome
             (CRPS)

          -  Open wound
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Taylor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saldana MJ. Trigger digits: diagnosis and treatment. J Am Acad Orthop Surg. 2001 Jul-Aug;9(4):246-52. Review.</citation>
    <PMID>11476534</PMID>
  </reference>
  <reference>
    <citation>Strom L. Trigger finger in diabetes. J Med Soc N J. 1977 Nov;74(11):951-4.</citation>
    <PMID>269967</PMID>
  </reference>
  <reference>
    <citation>Kasdan ML, Leis VM, Lewis K, Kasdan AS. Trigger finger: not always work related. J Ky Med Assoc. 1996 Nov;94(11):498-9.</citation>
    <PMID>8973080</PMID>
  </reference>
  <reference>
    <citation>Marks MR, Gunther SF. Efficacy of cortisone injection in treatment of trigger fingers and thumbs. J Hand Surg Am. 1989 Jul;14(4):722-7.</citation>
    <PMID>2754207</PMID>
  </reference>
  <reference>
    <citation>Lambert MA, Morton RJ, Sloan JP. Controlled study of the use of local steroid injection in the treatment of trigger finger and thumb. J Hand Surg Br. 1992 Feb;17(1):69-70.</citation>
    <PMID>1640148</PMID>
  </reference>
  <reference>
    <citation>Murphy D, Failla JM, Koniuch MP. Steroid versus placebo injection for trigger finger. J Hand Surg Am. 1995 Jul;20(4):628-31. Erratum in: J Hand Surg [Am] 1995 Nov;20(6):1075.</citation>
    <PMID>7594291</PMID>
  </reference>
  <reference>
    <citation>Maneerit J, Sriworakun C, Budhraja N, Nagavajara P. Trigger thumb: results of a prospective randomised study of percutaneous release with steroid injection versus steroid injection alone. J Hand Surg Br. 2003 Dec;28(6):586-9.</citation>
    <PMID>14599834</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <results_first_submitted>July 10, 2017</results_first_submitted>
  <results_first_submitted_qc>December 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Kenneth Taylor, M.D.</investigator_full_name>
    <investigator_title>Associate Professor, Orthopaedics</investigator_title>
  </responsible_party>
  <keyword>flexor tendon entrapment</keyword>
  <keyword>snapping finger</keyword>
  <keyword>trigger digits</keyword>
  <keyword>trigger thumb</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigger Finger Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Corticosteroid Alone (CS) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug</description>
        </group>
        <group group_id="P2">
          <title>Corticosteroid/Lidocaine (CSL) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Xylocaine: a local anesthetic agent</description>
        </group>
        <group group_id="P3">
          <title>Corticosteroid/Saline (CSS) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Sodium Chloride: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Corticosteroid Alone (CS) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug</description>
        </group>
        <group group_id="B2">
          <title>Corticosteroid/Lidocaine (CSL) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Xylocaine: a local anesthetic agent</description>
        </group>
        <group group_id="B3">
          <title>Corticosteroid/Saline (CSS) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Sodium Chloride: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="9"/>
                    <count group_id="B4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="9"/>
                    <count group_id="B4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="9"/>
                    <count group_id="B4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VAS</title>
        <description>Visual Analogue Pain Scale (VAS) - measurement of pain on scale of 0 (least) to 10 (worst).</description>
        <time_frame>Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, at 6 weeks post-injection and also asked to recollect their pain at time of injection when seen at 6 weeks post-injection</time_frame>
        <population>VAS was collected on all study participants except for the one patient (CSS group) who was withdrawn after enrollment and before any measurements were taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Corticosteroid Alone (CS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid/Lidocaine (CSL) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Xylocaine: a local anesthetic agent</description>
          </group>
          <group group_id="O3">
            <title>Corticosteroid/Saline (CSS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Sodium Chloride: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
          </group>
        </group_list>
        <measure>
          <title>VAS</title>
          <description>Visual Analogue Pain Scale (VAS) - measurement of pain on scale of 0 (least) to 10 (worst).</description>
          <population>VAS was collected on all study participants except for the one patient (CSS group) who was withdrawn after enrollment and before any measurements were taken.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS pre-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.0"/>
                    <measurement group_id="O2" value="3.0" spread="2.5"/>
                    <measurement group_id="O3" value="3.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS 1 minute post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.2"/>
                    <measurement group_id="O2" value="2.2" spread="2.6"/>
                    <measurement group_id="O3" value="4.9" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS 10 minutes post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.3"/>
                    <measurement group_id="O2" value="1.2" spread="1.7"/>
                    <measurement group_id="O3" value="3.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS 6 weeks post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.6"/>
                    <measurement group_id="O2" value="3.3" spread="3.7"/>
                    <measurement group_id="O3" value="4.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Recollection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.3"/>
                    <measurement group_id="O2" value="6.6" spread="2.5"/>
                    <measurement group_id="O3" value="5.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Triggering</title>
        <description>Patients are asked how often their finger triggers - not at all, rarely, occasionally, or frequently at time intervals indicated in the outcome measure time frame. Count of participants for each of these answers was collected.</description>
        <time_frame>Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, and 6 weeks post-injection</time_frame>
        <population>All participants from three groups were asked this question. Data was not collected on subject (CSS group) that withdrew from study after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Corticosteroid Alone (CS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid/Lidocaine (CSL) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Xylocaine: a local anesthetic agent</description>
          </group>
          <group group_id="O3">
            <title>Corticosteroid/Saline (CSS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Sodium Chloride: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Triggering</title>
          <description>Patients are asked how often their finger triggers - not at all, rarely, occasionally, or frequently at time intervals indicated in the outcome measure time frame. Count of participants for each of these answers was collected.</description>
          <population>All participants from three groups were asked this question. Data was not collected on subject (CSS group) that withdrew from study after enrollment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triggering frequently pre-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering not at all pre-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering occasionally pre-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering rarely pre-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering not at all 1 minute post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering rarely 1 minute post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering occasionally 1 minute post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering frequently 1 minute post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering same as before 1 minute post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering not at all 10 minutes post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering rarely 10 minutes post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering occasionally 10 minutes post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering frequently 10 minutes post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering same as before 10 min. post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering not at all 6 wks post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering rarely 6 wks post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering occasionally 6 weeks post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triggering frequently 6 wks post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triggering same as before 6 wks post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Triggering</title>
        <description>A Green classification number (0-4) is given to each subject pre-injection and at 6 weeks post-injection based on their degree of triggering. 0 = No triggering, no pain; 1 = Pre-triggering; pain, history of catching, but not demonstrable on physical examination; tenderness over the A1 pulley; 2 = Active; demonstrable catching, but the patient can actively extend the digit; 3= Passive; demonstrable catching requiring passive extension or inability to actively flex; and 4 = Contracture; demonstrable catching with a fixed flexion contracture of the PIP joint.</description>
        <time_frame>Patients are assessed pre-injection objectively by investigator and at 6 weeks post-injection subjectively via Patient Survey</time_frame>
        <population>Data collected on all subjects enrolled except for one that was withdrawn after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Corticosteroid Alone (CS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid/Lidocaine (CSL) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Xylocaine: a local anesthetic agent</description>
          </group>
          <group group_id="O3">
            <title>Corticosteroid/Saline (CSS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Sodium Chloride: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Triggering</title>
          <description>A Green classification number (0-4) is given to each subject pre-injection and at 6 weeks post-injection based on their degree of triggering. 0 = No triggering, no pain; 1 = Pre-triggering; pain, history of catching, but not demonstrable on physical examination; tenderness over the A1 pulley; 2 = Active; demonstrable catching, but the patient can actively extend the digit; 3= Passive; demonstrable catching requiring passive extension or inability to actively flex; and 4 = Contracture; demonstrable catching with a fixed flexion contracture of the PIP joint.</description>
          <population>Data collected on all subjects enrolled except for one that was withdrawn after enrollment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Green classification 0 (pre-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 1 (pre-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 2 (pre-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 3 (pre-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green Classification 4 (pre-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 0 (6-weeks post-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 1 (6-weeks post-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 2 (6-weeks post-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 3 (6-weeks post-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green classification 4 (6-weeks post-injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Effects</title>
        <description>Incidence of adverse effects</description>
        <time_frame>Patients are assessed 1 minute post-injection, 10 minutes post-injection, and at 6 week post-injection.</time_frame>
        <population>Adverse effects was collected on all study participants except for the one patient who was withdrawn after enrollment (CSS group)</population>
        <group_list>
          <group group_id="O1">
            <title>Corticosteroid Alone (CS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid/Lidocaine (CSL) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Xylocaine: a local anesthetic agent</description>
          </group>
          <group group_id="O3">
            <title>Corticosteroid/Saline (CSS) Group</title>
            <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Sodium Chloride: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Effects</title>
          <description>Incidence of adverse effects</description>
          <population>Adverse effects was collected on all study participants except for the one patient who was withdrawn after enrollment (CSS group)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse effects 1 minute post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse effects 10 minutes post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse effects 6 weeks post-injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse effects were assessed 1 minute, 10 minutes, and 6 weeks post-injction</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Corticosteroid Alone (CS) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug</description>
        </group>
        <group group_id="E2">
          <title>Corticosteroid/Lidocaine (CSL) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Xylocaine: a local anesthetic agent</description>
        </group>
        <group group_id="E3">
          <title>Corticosteroid/Saline (CSS) Group</title>
          <description>1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
Dexamethasone Sodium Phosphate: adreno-cortical steroid anti-inflammatory drug
Sodium Chloride: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study closed prematurely on 1/25/2017 with 26 patients enrolled and 1 withdrawal.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kenneth Taylor, M.D.</name_or_title>
      <organization>Penn State Milton S. Hershey Medical Center</organization>
      <phone>(717) 531-5638</phone>
      <email>ktaylor2@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

